[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-adjuvant-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-adjuvant-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100615076","prediction-of-targeted-therapy-efficacy-in-egfr-mutant-lung-cancer-patients-using-ai-based-multimodal-data-100615076",false,"NCT07287904","Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data","A Retrospective Analysis Study on Predicting the Efficacy of Targeted Therapy in Lung Cancer Patients With EGFR Mutations Based on AI-driven Multimodal Data","Inclusion Criteria:\n\n1. Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);\n2. Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;\n3. EGFR gene testing positive, EGFR 19del\u002FL858R mutation;\n4. Receiving postoperative EGFR-TKI targeted adjuvant therapy;\n5. Complete and clear preoperative imaging data, genetic testing report, and pathology report available.\n\nExclusion Criteria:\n\n1. Patients negative for EGFR;\n2. Incomplete surgical resection (R1, R2);\n3. Did not receive EGFR-TKI targeted therapy after surgery;\n4. Recurrent or advanced stage patients;\n5. Incomplete preoperative or postoperative data;\n6. Patients who died within 30 days post-surgery.","ALL","18 Years","80 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.",[25,26,27,28],"Lung Cancer (NSCLC)","EGFR Activating Mutation","Adenocarcinoma Lung","Postoperative Adjuvant Therapy","NOT_YET_RECRUITING","2025-12-16",{"date":32,"type":33},"2025-12-17","ACTUAL",{"date":35,"type":21},"2025-12-25",{"date":37,"type":21},"2027-08",{"name":39,"class":40},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100575979","phase-4-maintenance-chemotherapy-with-s-1-vs-observation-after-adjuvant-therapy-for-resected-pancreatic-cancer-with-high-risk-of-recurrencemetastasis-100575979","NCT06779318","Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence\u002FMetastasis","A Real-World Study Comparing Maintenance Chemotherapy With Tegafur, Gimeracil, and Oteracil Potassium (S-1) Versus Follow-Up Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence\u002FMetastasis (MSPAC-1)","Inclusion Criteria:\n\n1. Histologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium);\n2. Meets one of the following conditions: Pathologically confirmed as moderately differentiated, moderately to poorly differentiated, or poorly differentiated; or pathologic staging as: T3N0M0, T1-3N1-2M0, T4N0-2M0; or one or more surgical margins are R1 resected (R0 resection if no tumor cells are found more than 1mm from the margin, otherwise R1 resection); or involvement of the portal vein and\u002For superior mesenteric vein resection; or pre-adjuvant chemotherapy CA19-9 \\> 90 U\u002FmL; or pre-adjuvant chemotherapy ctDNA testing positive;\n3. Completed standard treatment: Received radical resection, postoperative adjuvant therapy (including adjuvant chemotherapy based on gemcitabine or fluorouracil), and radiotherapy (if applicable);\n4. Eligible for oral medication;\n5. Age ≥18 and ≤75, male or female;\n6. ECOG performance status: 0 to 2;\n7. Normal function of major organs as per the following criteria within 14 days prior to starting treatment:① Neutrophil count ≥ 1.5×10\\^9\u002FL;② Platelet count ≥ 75×10\\^9\u002FL;③ Hemoglobin ≥ 9.0 g\u002FdL;④ AST ≤ 2.5×UNL (upper normal limit) (if liver metastasis present, AST ≤ 5×UNL);⑤ ALT ≤ 2.5×UNL (if liver metastasis present, ALT ≤ 5×UNL);⑥ Total bilirubin ≤ 1.5×UNL;⑦ Creatinine clearance (calculated using the Cockcroft-Gault formula) \\> 60 mL\u002Fmin or serum creatinine ≤ 1.5×UNL;\n8. Women of childbearing potential must have used reliable contraception within 7 days prior to enrollment and have a negative pregnancy test, and must be willing to use appropriate contraception during the study and for 6 months after the last dose of the investigational drug. For men, they must be surgically sterile or agree to use appropriate contraception during the study and for 3 months after treatment;\n9. Expected survival time ≥6 months;\n10. Voluntary participation in the study, signed informed consent, and demonstrated good compliance and cooperation during follow-up.\n\nExclusion Criteria:\n\n1. Pancreatic cancer originating from non-pancreatic ductal epithelium, including pancreatic neuroendocrine tumors, pancreatic acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary tumor;\n2. Incomplete macroscopic resection (R2 resection);\n3. Presence of distant metastasis (including malignant ascites and pleural effusion, peritoneal metastasis) or locally recurrent pancreatic cancer;\n4. CA19-9 \\> 180 U\u002FmL within 21 days before enrollment;\n5. Severe liver dysfunction (AST\u002FALT \\> 3.5 times the upper limit of normal, alkaline phosphatase \\> 6 times the upper limit of normal), with liver drainage;\n6. Known peripheral neuropathy (CTCAE ≥ Grade 2);\n7. Participation in another clinical trial of cytotoxic drugs, targeted therapies, immunotherapies, etc., within the past 4 weeks, or received systemic chemotherapy, radiotherapy, or biological therapy within the past 4 weeks;\n8. Concurrent or metachronous cancers with disease-free survival ≥ 5 years (excluding pancreatic cancer), except for cancers that have been cured or can be potentially cured with local excision (e.g., esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, non-melanoma skin cancer, bladder cancer);\n9. Factors that significantly affect oral drug absorption, such as difficulty swallowing, chronic diarrhea, or gastrointestinal obstruction; uncontrolled Crohn's disease or ulcerative colitis;\n10. Clinically symptomatic serous effusions (including pleural effusion, ascites, pericardial effusion) requiring symptomatic treatment;\n11. Pregnant or breastfeeding women; patients of childbearing potential unwilling or unable to take effective contraceptive measures;\n12. Known allergy to the investigational drug, the class of the investigational drug, or its components;\n13. Need for systemic corticosteroid treatment (except for local steroid pre-treatment);\n14. History of interstitial lung disease (including interstitial pneumonia, pulmonary fibrosis, etc.) or CT findings of interstitial lung disease;\n15. Active local or systemic infection requiring treatment;\n16. Heart failure NYHA classification ≥ II or severe heart disease;\n17. Known HIV infection or history of acquired immunodeficiency syndrome (AIDS) or active hepatitis B or C;\n18. Toxicity not recovered (CTCAE \\> Grade 1) or previous anticancer surgery not fully recovered;\n19. Patients deemed unsuitable for this study by the investigator.","75 Years",{"count":51,"type":21},464,"INTERVENTIONAL",[54],"PHASE4","The goal of this real-world study is to learn if maintenance chemotherapy with Tegafur, Gimeracil, and Oteracil Potassium (S-1) can improve disease-free survival (DFS) compared to follow-up observation in patients with resected pancreatic cancer at high risk of recurrence or metastasis after adjuvant therapy. The main questions it aims to answer are:\n\n* Does maintenance therapy with S-1 improve disease-free survival (DFS) compared to follow-up observation after standard treatment for resected high-risk pancreatic cancer?\n* Does S-1 maintenance therapy improve overall survival (OS), distant disease-free survival (DDFS), and local recurrence-free survival (LRFS) compared to observation?\n* What are the safety and tolerability profiles of S-1 maintenance therapy compared to observation? Researchers will compare two groups: the S-1 maintenance therapy group and the observation-only group, to see if S-1 improves survival outcomes and safety.\n\nParticipants will:\n\n* Receive maintenance chemotherapy with S-1 based on body surface area dosing or be assigned to the observation group without drug intervention.\n* Undergo imaging evaluations every 12 weeks to monitor for disease recurrence or metastasis.\n* Report side effects and any adverse events during the study.",[57,28,58],"Pancreatic Cancer","Maintenance Therapy",[58,60],"S-1","2025-04-02",{"date":63,"type":33},"2025-04-03",{"date":65,"type":21},"2025-07",{"date":67,"type":21},"2028-07",{"name":69,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":77,"targetDuration":4,"studyType":52,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100561913","phase-2-evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer-100561913","NCT06596343","Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer","Study on the Value of Traditional Chinese Medicine Precision Treatment Based on Syndrome Differentiation in Postoperative Adjuvant Therapy for Locally Advanced Colorectal Cancer","Inclusion Criteria:\n\n* 1\\. Age between 18 and 75 years. 2. Diagnosed with colorectal cancer at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and underwent standard radical colorectal cancer surgery. Postoperative pathological staging is stage III (AJCC 8th edition: T4, any N+, M0, or any T, N2, M0), indicating the need for chemotherapy according to the CSCO 2023 colorectal cancer guidelines.\n\n  3\\. Willing to receive Traditional Chinese Medicine (TCM) treatment. 4. Voluntarily agree to participate in the study and sign the informed consent form. If the subject is unable to read or sign the consent due to incapacity, the informed consent must be obtained from a legal guardian. If the subject cannot read the consent (e.g., illiterate subjects), a witness must observe and sign the consent process.\n\n  5\\. Expected survival of ≥12 months. 6. ECOG performance status score of 0-1. 7. No prior anti-cancer, immunotherapy, or radiation treatment. 8. Laboratory tests meeting the following criteria:\n* White blood cell count ≥3.5 × 10\\^9\u002FL, absolute neutrophil count ≥1.8 × 10\\^9\u002FL, platelet count ≥100 × 10\\^9\u002FL, hemoglobin ≥100 g\u002FL.\n* INR ≤1.5 and APTT ≤1.5 times the upper limit of normal (ULN) or PTT ≤1.5 times ULN.\n* Total bilirubin ≤1.25 times ULN; ALT and AST ≤3 times ULN; serum albumin ≥28 g\u002FL.\n* 24-hour creatinine clearance rate ≥50 mL\u002Fmin or serum creatinine ≤1.5 times ULN.\n\nExclusion Criteria:\n\n* 1\\. Colorectal cancer patients with distant metastasis as indicated by preoperative evaluation.\n\n  2\\. Postoperative pathological results indicate that chemotherapy is not required according to the CSCO 2023 colorectal cancer guidelines.\n\n  3\\. Patients who have received neoadjuvant chemoradiotherapy before surgery. 4. Patients with severe heart, liver, kidney damage, or bone marrow dysfunction.\n\n  5\\. Pregnant or breastfeeding women. 6. Patients with known allergies to Traditional Chinese Medicine components. 7. Patients who refuse chemotherapy or TCM treatment. 8. Patients with a history of mental illness or cognitive impairment.",{"count":78,"type":21},80,[80],"PHASE2","This study aims to explore the role of Traditional Chinese Medicine (TCM) based on syndrome differentiation in reducing chemotherapy side effects, lowering the risk of metastasis and recurrence, and improving survival rates in postoperative colorectal cancer patients through a prospective, single-arm interventional clinical trial.",[83,28],"Locally Advanced Colorectal Cancer","2024-09-10",{"date":86,"type":33},"2024-09-19",{"date":88,"type":21},"2024-10",{"date":90,"type":21},"2027-09-30",{"name":92,"class":40},"Sir Run Run Shaw Hospital"]